YM BioSciences public offering raises $80.5m
This article was originally published in Scrip
Executive Summary
YM Biosciences, a Canadian drug development company, has raised $80.5 million in its recent public offering, in one of the largest Canadian biotech offerings in recent years. The money will be used to fund development of CYT386, YM's Phase I/II JAK1/JAK2 inhibitor to treat myelofibrosis.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.